Canada markets open in 5 hours 3 minutes

Can-Fite BioPharma Ltd. (CANF)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
2.7300-0.4800 (-14.95%)
At close: 04:00PM EDT
2.7000 -0.03 (-1.10%)
After hours: 06:40PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close3.2100
Open3.0000
Bid2.4600 x 800
Ask2.7900 x 1000
Day's Range2.6100 - 3.0550
52 Week Range1.8100 - 4.4800
Volume208,269
Avg. Volume52,396
Market Cap13.624M
Beta (5Y Monthly)0.65
PE Ratio (TTM)N/A
EPS (TTM)-3.0000
Earnings DateJun 20, 2024 - Jun 28, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.00
  • Business Wire

    Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study

    PETACH TIKVA, Israel, June 10, 2024--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it received an approval from the Institutional Review Board (IRB) of Rabin Medical Center, a leading medical institution in Israel where the study will be conducted. The approved protocol has been submitted now to the Ministry of Health (MOH).

  • Business Wire

    Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study

    RAMAT GAN, Israel, June 05, 2024--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced an update on the status of its oncological lead drug candidate, Namodenoson in the treatment of advanced liver cancer. The Phase 3 pivotal study now has 31 recruiting medical centers in Europe, Israel and the US. Namodenoson has Orphan Drug status with both

  • Business Wire

    Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases

    RAMAT-GAN, Israel, May 29, 2024--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today reported that the International Journal of Molecular Sciences published a scientific review by independent scientists summarizing >50 publications from scientists all over the world stating that piclidenoson and namodenoson have a positive effect on heart diseases (Li